Excellent anti-proliferative and pro-apoptotic effects of (-)-epigallocatechin-3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 8, 2014, Pages 1619-1626

  Siddiqui, Imtiaz A ^a   Bharali, Dhruba J ^b   Nihal, Minakshi ^a   Adhami, Vaqar M ^a   Khan, Naghma ^a   Chamcheu, Jean Christopher ^a   Khan, Mohammad Imran ^a   Shabana, Sameh ^a,c   Mousa, Shaker A ^b   Mukhtar, Hasan ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c Mansoura University   (Egypt)

Author keywords

Chitosan; EGCG; Melanoma; Nanotechnology

Indexed keywords

CELL DEATH; CELL PROLIFERATION; CHITOSAN; DERMATOLOGY; DISEASES; MAMMALS; NANOPARTICLES; NANOTECHNOLOGY; TEA; TUMORS;

APOPTOSIS INDUCTION; CHITOSAN NANOPARTICLES; EGCG; EPIGALLOCATECHIN-3-GALLATE; GREEN TEA POLYPHENOLS; MELANOMA; PRO-APOPTOTIC EFFECTS; PROLIFERATION INHIBITION;

ONCOLOGY;

CHITOSAN; CHITOSAN NANOPARTICLE; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIGALLOCATECHIN GALLATE; KI 67 ANTIGEN; NANOPARTICLE; UNCLASSIFIED DRUG; CATECHIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DRUG FORMULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MELANOMA CELL; MELANOMA CELL LINE; MOUSE; NANOENCAPSULATION; NANOPHARMACEUTICS; NANOTECHNOLOGY; NONHUMAN; NUDE MOUSE; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; PROCEDURES; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; CHITOSAN; HUMANS; MALE; MELANOMA; MICE; MICE, NUDE; NANOPARTICLES; NANOTECHNOLOGY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84911991796     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.05.007     Document Type: Article

References (46)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Nihal M., Ahsan H., Siddiqui I.A., Mukhtar H., Ahmad N., Wood G.S. (-)-Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma. Cell Cycle 2009, 8:2057-2063.
3. Ivanov V.N., Bhoumik A., Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003, 22:3152-3161.
4. Hersey P., Zhang X.D. How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 2001, 1:142-150.
5. Nihal M., Ahmad N., Mukhtar H., Wood G.S. Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer 2005, 114:513-521.
6. Nihal M., Roelke C.T., Wood G.S. Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG). Pharm Res 2010, 27:1103-1114.
7. Uzarska M., Czajkowski R., Schwartz R.A., Bajek A., Zegarska B., Drewa T. Chemoprevention of skin melanoma: facts and myths. Melanoma Res 2013, 23:426-433.
8. Syed D.N., Mukhtar H. Botanicals for the prevention and treatment of cutaneous melanoma. Pigment Cell Melanoma Res 2011, 24:688-702.
9. Francis S.O., Mahlberg M.J., Johnson K.R., Ming M.E., Dellavalle R.P. Melanoma chemoprevention. J Am Acad Dermatol 2006, 55:849-861.
10. Farina H.G., Pomies M., Alonso D.F., Gomez D.E. Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. Oncol Rep 2006, 16:885-891.
11. Bailey H.H., Mukhtar H. Green tea polyphenols and cancer chemoprevention of genitourinary cancer. American Society of Clinical Oncology educational book/ASCO American Society of Clinical Oncology Meeting 2013, 33:92-96.
12. Khan N., Mukhtar H. Tea and health: studies in humans. Curr Pharm Des 2013, 19:6141-6147.
13. Siddiqui I.A., Tarapore R.S., Mukhtar H. Prevention of skin cancer by green tea: past, present and future. Cancer Biol Ther 2009, 8:1288-1291.
14. Butt M.S., Sultan M.T. Green tea: nature's defense against malignancies. Crit Rev Food Sci Nutr 2009, 49:463-473.
15. Siddiqui I.A., Adhami V.M., Bharali D.J., Hafeez B.B., Asim M., Khwaja S.I., et al. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 2009, 69:1712-1716.
16. Khan N., Bharali D.J., Adhami V.M., Siddiqui I.A., Cui H., Shabana S.M., et al. Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis 2014, 35:415-423.
17. Siddiqui I.A., Malik A., Adhami V.M., Asim M., Hafeez B.B., Sarfaraz S., et al. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 2008, 27:2055-2063.
18. Siddiqui I.A., Zaman N., Aziz M.H., Reagan-Shaw S.R., Sarfaraz S., Adhami V.M., et al. Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas. Carcinogenesis 2006, 27:833-839.
19. Cory S., Huang D.C., Adams J.M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003, 22:8590-8607.
20. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281:1322-1326.
21. Yu S.W., Andrabi S.A., Wang H., Kim N.S., Poirier G.G., Dawson T.M., et al. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci U S A 2006, 103:18314-18319.
22. Lee Y.M., Sicinski P. Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human. Cell Cycle 2006, 5:2110-2114.
23. Li J.M., Brooks G. Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy?. Eur Heart J 1999, 20:406-420.
24. Siddiqui I.A., Adhami V.M., Chamcheu J.C., Mukhtar H. Impact of nanotechnology in cancer: emphasis on nanochemoprevention. Int J Nanomedicine 2012, 7:591-605.
25. Siddiqui I.A., Adhami V.M., Ahmad N., Mukhtar H. Nanochemoprevention: sustained release of bioactive food components for cancer prevention. Nutr Cancer 2010, 62:883-890.
26. Siddiqui I.A., Mukhtar H. Nanochemoprevention by bioactive food components: a perspective. Pharm Res 2010, 27:1054-1060.
27. Wang D., Taylor E.W., Wang Y., Wan X., Zhang J. Encapsulated nanoepigallocatechin-3-gallate and elemental selenium nanoparticles as paradigms for nanochemoprevention. Int J Nanomedicine 2012, 7:1711-1721.
28. Sanna V., Siddiqui I.A., Sechi M., Mukhtar H. Nanoformulation of natural products for prevention and therapy of prostate cancer. Cancer Lett 2013, 334:142-151.
29. Ribeiro A.F., de Oliveira Rezende R.L., Cabral L.M., de Sousa V.P. Poly varepsilon-caprolactone nanoparticles loaded with Uncaria tomentosa extract: preparation, characterization, and optimization using the Box-Behnken design. Int J Nanomedicine 2013, 8:431-442.
30. Grandhi B.K., Thakkar A., Wang J., Prabhu S. A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions. Cancer Prev Res 2013, 6:1015-1025.
31. Moseley V.R., Morris J., Knackstedt R.W., Wargovich M.J. Green tea polyphenol epigallocatechin 3-gallate, contributes to the degradation of DNMT3A and HDAC3 in HCT 116 human colon cancer cells. Anticancer Res 2013, 33:5325-5333.
32. Tao L., Forester S.C., Lambert J.D. The role of the mitochondrial oxidative stress in the cytotoxic effects of the green tea catechin, (-)-epigallocatechin-3-gallate, in oral cells. Mol Nutr Food Res 2014, 58:665-676.
33. Khan N., Mukhtar H. Modulation of signaling pathways in prostate cancer by green tea polyphenols. Biochem Pharmacol 2013, 85:667-672.
34. Siddiqui I.A., Asim M., Hafeez B.B., Adhami V.M., Tarapore R.S., Mukhtar H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J 2011, 25:1198-1207.
35. Wang P., Vadgama J.V., Said J.W., Magyar C.E., Doan N., Heber D., et al. Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea. J Nutr Biochem 2014, 25:73-80.
36. Jankun J., Keck R.W., Selman S.H. Epigallocatechin-3-gallate prevents tumor cell implantation/growth in an experimental rat bladder tumor model. Int J Oncol 2014, 44:147-152.
37. Adhami V.M., Malik A., Zaman N., Sarfaraz S., Siddiqui I.A., Syed D.N., et al. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2007, 13:1611-1619.
38. Shanafelt T.D., Call T.G., Zent C.S., Leis J.F., LaPlant B., Bowen D.A., et al. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer 2013, 119:363-370.
39. Stingl J.C., Ettrich T., Muche R., Wiedom M., Brockmöller J., Seeringer A., et al. Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population. BMC Cancer 2011, 11:360.
40. Kurahashi N., Sasazuki S., Iwasaki M., Inoue M., Tsugane S., Group J.S. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol 2008, 167:71-77.
41. Bettuzzi S., Brausi M., Rizzi F., Castagnetti G., Peracchia G., Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006, 66:1234-1240.
42. Adhami V.M., Aziz M.H., Reagan-Shaw S.R., Nihal M., Mukhtar H., Ahmad N. Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery. Mol Cancer Ther 2004, 3:933-940.
43. Singh R.P., Dhanalakshmi S., Agarwal R. Phytochemicals as cell cycle modulators-a less toxic approach in halting human cancers. Cell Cycle 2002, 1:156-161.
44. Cuddihy A.R., O'Connell M.J. Cell-cycle responses to DNA damage in G2. Int Rev Cytol 2003, 222:99-140.
45. Scholzen T., Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000, 182:311-322.
46. Leonardi E., Girlando S., Serio G., Mauri F.A, Perrone G., Scampini S., et al. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol 1992, 45:416-419.